-
Mashup Score: 5FDA approves updated label for Lupkynis with long-term data, new monitoring guidelines - 3 day(s) ago
The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments. The new label for Lupkynis (voclosporin, Aurinia Pharmaceuticals) now accounts for a post-hoc analysis of 3-year data from a double-blind, placebo-controlled extension study,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
Aerobic and resistance training are recommended for patients with systemic lupus erythematosus, but should be tailored to the individual and, ideally, supervised by a professional, according to recommendations published in RMD Open. “Despite the clear potential benefits, incorporating physical activity and exercise into the lives of persons living with SLE presents unique challenges,”
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 11
LuGENE, a blood test to predict lupus flares and quickly identify drug targets, is being made available to patients around the United States through an open-label study, according to a press release from the manufacturer. Recruitment is ongoing for the multicenter study, called ReLATE, testing how LuGENE’s (AMPEL BioSolutions) results correlate with standard evaluation of patients with
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Adding Antimalarials to Belimumab Better Protects Against Lupus Renal Flares - Renal and Urology News - 30 day(s) ago
Maintaining immunosuppressive/biological treatment for at least 3 to 5 years may help reduce flare risk, data suggest.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Lupus racial disparities worse in children’s hospitals that serve more Black patients - 1 month(s) ago
Disparities in lupus ICU admission and renal outcomes between Black and white children are greater in children’s hospitals serving more Black patients, according to data published in Arthritis Care & Research.“Clinicians will recognize that the relationship between health care disparities and the characteristics of the communities they serve is really complicated —
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
Beyond anti-dsDNA, anti-Sm and anti-ribosomal P protein antibody positivity may have value in surveillance of renal SLE.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Echocardiographic Screening Needed for Patients With SLE at Risk for Pulmonary Hypertension - Renal and Urology News - 2 month(s) ago
Researchers assessed the prevalence, main echocardiographic predictors, and risk factors for pulmonary hypertension in patients with systemic lupus erythematosus.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0The Lupus Butterfly Effect - 2 month(s) ago
Taking steps today to understand more about Systemic Lupus Erythematosus (SLE) could make a big difference to your future. Learn more today.
Source: lupusbutterflyeffect.comCategories: General Medicine News, PayerTweet-
Organ damage in #lupus occurs when the immune system attacks and inflames organs. This could be prevented for some patients if timely action is taken. Talk with a doctor early to determine what next steps in a treatment plan may be. Listen to Isha’s story: https://t.co/T11N85bALQ https://t.co/oENxgi53Hw
-
-
Mashup Score: 14
Objectives To unveil biological milieus underlying low disease activity (LDA) and remission versus active systemic lupus erythematosus (SLE). Methods We determined differentially expressed pathways (DEPs) in SLE patients from the PRECISESADS project (NTC02890121) stratified into patients fulfilling and not fulfilling the criteria of (1) Lupus LDA State (LLDAS), (2) Definitions of Remission in SLE remission, and (3) LLDAS exclusive of remission. Results We analysed data from 321 patients; 40.8% were in LLDAS, and 17.4% in DORIS remission. After exclusion of patients in remission, 28.3% were in LLDAS. Overall, 604 pathways differed significantly in LLDAS versus non-LLDAS patients with an false-discovery rate-corrected p (q)<0.05 and a robust effect size (dr)≥0.36. Accordingly, 288 pathways differed significantly between DORIS remitters and non-remitters (q<0.05 and dr≥0.36). DEPs yielded distinct molecular clusters characterised by differential serological, musculoskeletal, and renal act
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet-
Which molecular pathways differ in #lupus low disease activity state and remission?🤔 RNA sequencing from whole blood showed non-substantial pathway differentiation, suggesting a minimal added modulation at a biological level between these two states. https://t.co/5tSjI3weWu https://t.co/s8pHCRYJS3
-
-
Mashup Score: 0
The FDA has cleared an investigational new drug application for an allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of systemic lupus erythematosus with lupus nephritis, according to the manufacturer.The therapy, developed by Atara Biotherapeutics and currently known as ATA3219, is based on the company’s novel allogeneic Epstein-Barr virus T-cell platform and
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
📢@US_FDA has approved an updated label for Lupkynis by @AuriniaPharma, an oral treatment for active #lupus nephritis New label includes long-term safety & tolerability data + eases requirement for monthly kidney function checks Check Healio for more👇 https://t.co/DOYOX9biAE